The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

Publication | Closed Access

DOI

155

Citations

References

2008

Year

Christian Buske, Eva Hoster, Martin Dreyling, Hartmut Eimermacher, H. Wandt, Bernd Metzner, Roland J. Fuchs, J. Bittenbring, Bernhard J. Woermann, Karin Hohloch,

Leukemia

Lymphoid NeoplasiaOncologyImmunologyHigher Response RateLymphoplasmacytic LymphomaRandomized TrialImmunotherapyMedicineCancer Research